|
Basic Characteristics of Mutations
|
|
Mutation Site
|
A200V |
|
Mutation Site Sentence
|
At the start of combinatory therapy, HBV had LAM resistant primary mutation (rtM204I) and two secondary or novel mutations (rtI187L+rtA200V). |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
RT |
|
Standardized Encoding Gene
|
P
|
|
Genotype/Subtype
|
A |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
Hepatitis B, Chronic
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
Lamivudine(LAM) |
|
Location
|
Spain |
|
Literature Information
|
|
PMID
|
21911882
|
|
Title
|
Evolution of hepatitis B virus during long-term therapy in patients with chronic hepatitis B
|
|
Author
|
Arrese E,Basaras M,Blanco S,Ruiz P,Cisterna R
|
|
Journal
|
Annals of hepatology
|
|
Journal Info
|
2011 Oct-Dec;10(4):434-40
|
|
Abstract
|
BACKGROUND: Long-term lamivudine (LAM), adefovir (ADV) and entecavir (ETV) treatment induce the emergence of drug-resistant hepatitis B virus (HBV) in patients with chronic hepatitis B infection. AIM: To evaluate the LAM, ADV and ETV resistance mutations detected in our patient group. MATERIALS AND METHODS: Twenty patients who had received at least two years of treatment with nucleoside/tide analogues were enrolled in this study. Patients with detectable HBV DNA were analyzed in order to detect resistance mutations and in this group of patients treatment was change. RESULTS: Three patients developed LAM resistance mutations (2 presented rtM204I and one rtL180M+rtM204V/I) and one patient showed rtN236T ADV resistance mutation. During ADV and LAM treatment, one patient developed ADV plus LAM resistance mutations (rtI163V+rtL180M+rtA181V+rtN236T), in this case, HBV strains harbouring polymerase mutations did not develop LAM associated rtM204V/I primary mutation. In addition, ETV resistance mutations (rtL180M+rtT184A+rtS202G+rtM204V) were detected in one patient. CONCLUSIONS: These findings suggest that monotherapy resulted in a limited virological response and combination strategies including potent antiviral agents should be recommended for patients with resistant mutations.
|
|
Sequence Data
|
-
|